The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Lyell Immunopharma Inc’s stock clocked out at $0.58, up 8.48% from its previous closing price of $0.53. In other words, the price has increased by $8.48 from its previous closing price. On the day, 1.29 million shares were traded. LYEL stock price reached its highest trading level at $0.5879 during the session, while it also had its lowest trading level at $0.5211.
Ratios:
To gain a deeper understanding of LYEL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.06 and its Current Ratio is at 7.06. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.13.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BofA Securities on October 30, 2024, Downgraded its rating to Underperform and sets its target price to $1 from $6 previously.
On June 27, 2024, H.C. Wainwright Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $6 to $1.
JP Morgan Downgraded its Overweight to Neutral on August 28, 2023, whereas the target price for the stock was revised from $15 to $5.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 14 ’25 when Klausner Richard bought 158,000 shares for $0.60 per share. The transaction valued at 94,942 led to the insider holds 843,365 shares of the business.
Newton Charles W. bought 200,000 shares of LYEL for $111,620 on Mar 17 ’25. The Chief Financial Officer now owns 200,000 shares after completing the transaction at $0.56 per share. On Mar 14 ’25, another insider, Seely Lynn, who serves as the President and CEO of the company, bought 175,000 shares for $0.61 each. As a result, the insider paid 106,190 and bolstered with 712,500 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LYEL now has a Market Capitalization of 170789968 and an Enterprise Value of -140769104. For the stock, the TTM Price-to-Sale (P/S) ratio is 2846.50 while its Price-to-Book (P/B) ratio in mrq is 0.45. Its current Enterprise Value per Revenue stands at -2307.69 whereas that against EBITDA is 0.706.
Stock Price History:
The Beta on a monthly basis for LYEL is -0.29, which has changed by -0.6984375 over the last 52 weeks, in comparison to a change of 0.086116076 over the same period for the S&P500. Over the past 52 weeks, LYEL has reached a high of $3.14, while it has fallen to a 52-week low of $0.48. The 50-Day Moving Average of the stock is -5.94%, while the 200-Day Moving Average is calculated to be -49.71%.
Shares Statistics:
It appears that LYEL traded 1.04M shares on average per day over the past three months and 1009340 shares per day over the past ten days. A total of 294.88M shares are outstanding, with a floating share count of 125.07M. Insiders hold about 57.45% of the company’s shares, while institutions hold 22.48% stake in the company. Shares short for LYEL as of 1740700800 were 8087277 with a Short Ratio of 7.78, compared to 1738281600 on 11525095. Therefore, it implies a Short% of Shares Outstanding of 8087277 and a Short% of Float of 3.73.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
